Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
PfizerXSWX:PFE +1.20%63 EV-to-EBITDA is 11.35 as of Jul. 16, 2026, which is 10% below its 10-year median of 12.67. GuruFocus rates XSWX:PFE with a GF Score™ of 63/100 and a GF Value™ of CHF21.07 (Fairly Valued). The stock has 5 warning signs investors should review. Among 740 Drug Manufacturers companies, Pfizer ranks better than 58.65% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Pfizer's enterprise value is CHF155,714 Mil.
Pfizer's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was CHF13,719 Mil. Therefore, Pfizer's EV-to-EBITDA for today is 11.35.
The historical rank and industry rank for Pfizer's EV-to-EBITDA or its related term are showing as below:
XSWX:PFE'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 5.82 Med: 12.67 Max: 59.08
Current: 11.2
During the past 13 years, the highest EV-to-EBITDA of Pfizer was 59.08. The lowest was 5.82. And the median was 12.67.
XSWX:PFE's EV-to-EBITDA is ranked better than 58.65% of 740
companies
in the Drug Manufacturers industry
Industry Median: 13.025
vs XSWX:PFE: 11.20
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
As of today (2026-07-16), Pfizer's stock price is CHF19.876.
Pfizer's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was CHF1.048. Therefore, Pfizer's PE Ratio (TTM) for today is 18.97.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).
Pfizer (XSWX:PFE) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Pfizer's share price for today is CHF19.876.
Pfizer's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was CHF1.048.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Pfizer's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XSWX:PFE vs GILD, BMY, AMGN: EV-to-EBITDA Comparison
For the Drug Manufacturers - General subindustry, Pfizer's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pfizer EV-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Pfizer's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Pfizer's EV-to-EBITDA falls into.
Pfizer's current Enterprise Value is CHF155,714 Mil.
Pfizer's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was CHF13,719 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pfizer (XSWX:PFE) has a EV-to-EBITDA of 11.35 as of Jul. 16, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Pfizer. This is 10% below median its historical median of 12.67. Over the past decade, Pfizer's EV-to-EBITDA has ranged from 5.82 to 59.08. According to the industry distribution chart, Pfizer ranks #306 out of 740 companies in the Drug Manufacturers industry, placing it in the top 41.4%.
Is Pfizer's EV-to-EBITDA too high?
Pfizer's current EV-to-EBITDA of 11.35 is 10% below median its 10-year median of 12.67. Over the past 10 years, this metric has ranged from a low of 5.82 to a high of 59.08. The Drug Manufacturers industry median EV-to-EBITDA is 13.03. Pfizer's value of 11.35 is 12.9% below this industry median. Based on the distribution chart, Pfizer ranks #306 out of 740 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Pfizer has a GF Score™ of 63/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Pfizer's EV-to-EBITDA compare to GILD and BMY?
According to the Drug Manufacturers industry distribution chart, Pfizer ranks #306 out of 740 companies for EV-to-EBITDA. This puts Pfizer in the upper half of its industry. The industry median EV-to-EBITDA is 13.03. Pfizer's value of 11.35 is 12.9% below this benchmark. Historically, Pfizer's own EV-to-EBITDA has ranged from 5.82 to 59.08 over the past decade. While the company's 10-year median is 12.67 vs. the industry median of 13.03, Pfizer has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Drug Manufacturers company?
The median EV-to-EBITDA among Drug Manufacturers companies is 13.03, based on 740 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Pfizer's current EV-to-EBITDA of 11.35 is 12.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Pfizer. For the Drug Manufacturers industry, the median EV-to-EBITDA is 13.03 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Pfizer's current EV-to-EBITDA is 11.35, which is 10% below median its own 10-year median of 12.67. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pfizer stock overvalued right now?
Based on GuruFocus' analysis, Pfizer (XSWX:PFE) is currently considered Fairly Valued. The stock's GF Value™ is CHF21.07, compared to a current price of CHF19.88 — trading 5.7% below its estimated fair value. The current EV-to-EBITDA is 11.35, which is 10% below median its 10-year median of 12.67 and 12.9% below the Drug Manufacturers industry median of 13.03. Pfizer's overall GF Score™ is 63/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Pfizer (XSWX:PFE), the current EV-to-EBITDA is 11.35 as of Jul. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Pfizer (XSWX:PFE) Overvalued in 2026?
Based on GuruFocus' analysis, Pfizer stock appears to be undervalued.
The current stock price of CHF19.88 is trading 5.7% below its estimated GF Value™ of CHF21.07.
GuruFocus considers Pfizer to be Fairly Valued.
Key valuation signals for XSWX:PFE:
EV-to-EBITDA: 11.35 (10% below median its 10-year median of 12.67)
GF Value™: CHF21.07 vs. price of CHF19.88 (5.7% below fair value)
Industry Position: 12.9% below the Drug Manufacturers median (#306 of 740)
No single metric tells the full story. See the XSWX:PFE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Pfizer is one of the world's largest pharmaceutical firms, with annual sales of roughly $60 billion. While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13 and cardiology drugs Vyndaqel and Eliquis. Pfizer sells these products globally, with international sales representing 40% of total sales. Within international sales, emerging markets are a major contributor.
63GF Score
Get the complete analysis for XSWX:PFE
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:PFE has been successfully added to your 
